Epithalon, also known as Epitalon, Epithalone, or AEDG peptide, is a synthetic tetrapeptide composed of the amino acid sequence alanine-glutamic acid-aspartic acid-glycine (Ala-Glu-Asp-Gly). It was developed from Epithalamin, a naturally occurring polypeptide extract isolated from the pineal gland, and has been studied primarily for its potential effects on aging, telomere biology, circadian rhythm, melatonin production, and cellular repair.
Epithalon has attracted significant interest in longevity research because laboratory studies suggest it may activate telomerase, the enzyme responsible for maintaining telomeres, which protect the ends of chromosomes during cell division. Additional research has investigated its effects on oxidative stress, immune regulation, neuroprotection, and mitochondrial function. However, much of the published literature originates from laboratory studies, animal research, and clinical investigations performed outside the United States, and many findings require confirmation in larger, well-designed randomized clinical trials.
Epithalon is not FDA-approved for any medical indication in the United States.
The precise mechanism of action of Epithalon has not been completely established, but several biologic pathways have been proposed.
Research suggests Epithalon may:
Unlike hormone replacement therapies, Epithalon appears to function by influencing cellular regulatory pathways rather than replacing a deficient hormone. Most mechanistic evidence comes from laboratory and animal studies.
Published research suggests Epithalon may have several biologic effects.
Potential benefits may include:
Although these findings are promising, the majority of evidence comes from laboratory research, animal studies, and relatively small clinical studies. At present, there is insufficient evidence to conclude that Epithalon prolongs human lifespan or prevents age-related disease.
Because Epithalon has not been approved for therapeutic use in the United States, its complete safety profile has not been established.
Potential adverse effects may include:
One laboratory study demonstrated that Epithalon increased telomere length in both normal and certain cancer cell lines through different pathways. While this finding was obtained in vitro and does not demonstrate harm in humans, it underscores the need for additional research before widespread clinical use, particularly in patients with active or prior malignancy.
Formal contraindications have not been established because Epithalon is not an FDA-approved medication.
Based on current knowledge, Epithalon should generally be avoided or used only with specialist supervision in individuals with:
Individuals with significant medical conditions should consult a qualified healthcare provider before considering investigational peptide therapies.
Epithalon is NOT FDA-approved for any medical indication in the United States.
It is not FDA-approved for:
Although Epithalon has been investigated in human studies—primarily outside the United States—it remains an investigational compound and is not recognized as an approved drug by the FDA.
Human Studies
Human research on Epithalon has been conducted primarily in Russia and Eastern Europe.
Clinical investigations have evaluated Epithalon for:
Some published studies have reported improvements in melatonin secretion, retinal function, circadian rhythm, and selected health outcomes in older adults. However, many of these studies are relatively small, have limited methodological detail by modern standards, or require independent replication. Large multicenter randomized controlled trials meeting current international standards are lacking.
Animal & Preclinical Studies
Most evidence supporting Epithalon comes from laboratory and animal research.
Animal studies have demonstrated that Epithalon may:
While these findings are scientifically interesting, results from animal studies do not necessarily translate into similar clinical outcomes in humans.
Human Studies
Animal & Preclinical Studies
Review Articles
The information provided on this page is intended for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease and should not be considered medical advice.
This content was generated with the assistance of artificial intelligence (AI) and should be reviewed by a qualified medical professional before publication or clinical use. AI-generated medical content may contain errors, omissions, outdated information, or incomplete interpretations of the available scientific literature.
Epithalon (Epitalon) is not FDA-approved for any medical indication in the United States. Most published evidence consists of laboratory studies, animal research, and limited human clinical investigations. Larger, high-quality randomized controlled trials are needed to better define its safety and efficacy. Individual results vary, and no specific outcome or benefit can be guaranteed. Patients should consult a qualified healthcare provider before beginning or changing any medical treatment.
R2 Medical Clinic uses medications sourced from compounding pharmacies. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). Unlike FDA-approved medications, compounded drugs have not undergone FDA review for safety, effectiveness, or efficacy through the FDA drug approval process. While 503B outsourcing facilities are registered with and inspected by the FDA and must comply with Current Good Manufacturing Practice (CGMP) requirements, the compounded medications they produce are not individually approved by the FDA. Similarly, compounded medications prepared by 503A pharmacies are not FDA-approved and are primarily regulated by state boards of pharmacy, with FDA oversight under applicable federal law.
# AOD-9604